Clinical Trial

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

Study acronym: ORCHID
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1 criteria.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2018-12-21; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2019-06-03
Trial Details
NCT Number NCT03786796
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: AstraZeneca
Conditions Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer, Renal Carcinoma, Kidney Cancer Metastatic
Enrollment 20 participants
Start Date 2019-06-03
Primary Completion 2027-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-30